January 3, 2018 / 12:16 PM / 9 months ago

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

Jan 3 (Reuters) - Omeros Corp:

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

* OMEROS CORP - ‍INITIATES OMS721 PHASE 3 PROGRAM IN HCT-TMA​

* OMEROS CORP - ‍ PATIENT ENROLLMENT FOR ITS PHASE 3 CLINICAL TRIAL EVALUATING OMS721 IN PATIENTS WITH IGA NEPHROPATHY IS EXPECTED TO BEGIN EARLY IN FEB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below